Valeant's CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges. Source: BioSpace

MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial. Source: BioSpace

The feud stems from a Florida-based pharmaceutical startup, Altor BioScience, which Cher invested in. Source: BioSpace

Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology Source: BioSpace

Boragen is located in Research Triangle Park in Durham, N.C., and focuses on boron-based development of anti-bacterials and anti-fungicides for the agricultural industry. Source: BioSpace

GlaxoSmithKline CEO Emma Walmsley is eying a big acquisition to spur revenue growth but is making sure that her company will not overpay. Source: BioSpace

Dr. Erwin Erfe, head of the PAO Forensic Laboratory, said the 4 children they examined contracted dengue 6 months after receiving the vaccine. Source: BioSpace

For multiple perspectives on addressing this challenge, three respected individuals involved with the effort to bridge clinical research and clinical health care share their views. Source: BioSpace

Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers for the offering. Source: BioSpace

Vivek Ramaswamy's Axovant has egg on its face after it was forced to own up to the fact it misreported mid-stage data on a drug it hoped to take into…